Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group.
Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group.
复制标题
DOI：
10.1002/cncr.24566
复制
发表时间：
2009-11-15
期刊：
影响因子：
6.2
通讯作者：
Meyers, Paul A.
中科院分区：
文献类型：
--
作者：
Chou, Alexander J.;Kleinerman, Eugenie S.;Krailo, Mark D.;Chen, Zhengjia;Betcher, Donna L.;Healey, John H.;Conrad, Ernest U., III;Nieder, Michael L.;Weiner, Michael A.;Wells, Robert J.;Womer, Richard B.;Meyers, Paul A.
在化疗中加入脂质体胞壁酰三肽磷脂酰乙醇胺（L-MTPPE）已被证明可改善非转移性骨肉瘤（OS）患者的总生存期。我们报告了L-MTP-PE加化疗治疗转移性OS患者的结果。Intergroup-0133（INT-0133）是一项治疗新诊断的OS患者的前瞻性随机III期试验。我们比较了顺铂、多柔比星和大剂量甲氨蝶呤（方案A）与加异环磷酰胺（方案B）的三种药物化疗。我们评估了L-MTP-PE加化疗。接受L-MTP-PE治疗的患者（n=46）的5年EFS为42%，未接受L-MTP-PE治疗的患者（n=45）的5年EFS为26%（L-MTP-PE的相对风险：0.72，p=0.23，95% CI：0.42-1.2）。接受MTP-PE与未接受MTP-PE的患者的5年总生存率分别为53%和40%（L-MTP-PE的相对风险：0.72，p=0.27，95%CI：0.40-1.3）。方案A与方案B的比较未表明EFS（分别为35% v. 34%，方案B的相对风险：1.07，p=0.79，95% CI：0.62-1.8）或总生存期（分别为52% v. 43%，方案B的相对风险：1.1，p=0.75，95% CI：0.61-2.0）存在差异。当孤立地考虑转移性队列时，在化疗中加入L-MTPPE并没有实现统计学显著的结局改善。然而，结果的模式与非转移性患者的模式相似。
The addition of liposomal muramyl tripeptide phosphatidylethanolamine (L-MTPPE) to chemotherapy has been shown to improve overall survival in patients with non-metastatic osteosarcoma (OS). We report the results of L-MTP-PE addition to chemotherapy for patients with metastatic OS. Intergroup-0133 (INT-0133) was a prospective randomized phase III trial for the treatment of newly diagnosed patients with OS. We compared three drug chemotherapy with cisplatin, doxorubicin, and high-dose methotrexate (Regimen A) to the same three drugs with the addition of ifosfamide (Regimen B). We evaluated the addition of L-MTP-PE to chemotherapy. Five-year EFS for patients who received L-MTP-PE (n=46) was 42% versus 26% for those who did not (n=45) (relative risk for L-MTP-PE: 0.72, p=0.23, 95% CI: 0.42-1.2). The 5-year overall survival for patients who received MTP-PE versus no MTP-PE was 53% and 40% respectively (relative risk for L-MTP-PE: 0.72, p=0.27, 95% CI: 0.40-1.3). The comparison of Regimen A with regimen B did not suggest a difference for EFS (35% v. 34% respectively, relative risk for regimen B: 1.07, p=0.79, 95% CI: 0.62-1.8) or overall survival (52% v. 43% respectively, relative risk for regimen B: 1.1, p=0.75, 95% CI: 0.61-2.0). When the metastatic cohort was considered in isolation, the addition of L-MTPPE to chemotherapy did not achieve a statistically significant improvement in outcome. However, the pattern of outcome is similar to the pattern in nonmetastatic patients.
登录
查看更多内容
影响因子：
45.3
作者：
Meyers, PA;Gorlick, R;Healey, JH
通讯作者：
Healey, JH
影响因子：
45.3
作者：
MEYERS, PA;HELLER, G;LAQUAGLIA, M
通讯作者：
LAQUAGLIA, M
DOI：
10.1097/01.mph.0000150739.73067.f3
发表时间：
2005-01-01
影响因子：
1.2
作者：
del Prever, AB;Fagioli, F;Mercuri, M
通讯作者：
Mercuri, M
影响因子：
45.3
作者：
Kager, L;Zoubek, A;Bielack, SS
通讯作者：
Bielack, SS
影响因子：
3.9
作者：
ASANO, T;KLEINERMAN, ES
通讯作者：
KLEINERMAN, ES